The diabetes business leg of French pharmaceutical company Sanofi has decreased in size in the first three months of the year, according to the Q1 quarterly report which was published early Wednesday.
Sanofi's total sales of diabetes drugs fell by 1.7 percent in the first quarter, landing at EUR 1.2bn (USD 1.4bn).
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.